Biotech Values

[oc631]

I am aware of the lower dosing, and I'm not accusing Welch of misleading investors, but I'm starting to see a negative trend in development. The fact that 7227 needs ritonavir boosting should raise a red flag. Will it still meet the definition of a DAA when boosted with ritonavir in combination with RG7128? It seems Roche will wait for safety results in 7227 with SOC before pushing forward in Inform-3. I think Pharmasset's release stating Roche is evaluating the potential of RG7128 with other stat-c compounds shows who the weak partner is.